Compare CET & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | NBTX |
|---|---|---|
| Founded | 1929 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2018 |
| Metric | CET | NBTX |
|---|---|---|
| Price | $52.37 | $37.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 40.2K | ★ 80.4K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.76 | $4.93 |
| 52 Week High | $54.65 | $57.14 |
| Indicator | CET | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 48.16 |
| Support Level | $52.23 | $30.15 |
| Resistance Level | $52.52 | $38.29 |
| Average True Range (ATR) | 0.64 | 2.36 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 40.00 | 31.07 |
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.